Kornimate/medical-research-clean huggingface dataset:
clinical performance and wear resistance of highly translucent nano zirconia reinforced glass ionomer filling versus conventional resin composite restorations in patients with proximal carious teeth. (a one-year randomized clinical trial).

Conditions: Dental Caries

Summary: this randomized clinical study aims to evaluate the clinical performance and occlusal wear resistance of nano-zirconia reinforced glass ionomer restorations in comparison to nano-hybrid resin composite in proximal cavities.

statement of the problem: the glass ionomer restorations have a wide use in dental community. proximal restoration is a challenge, due to the high forces present in this area that require more high fracture resistance restoration material which is not obtained in the most of the versions of glass ionomer restorations that are available in dental market.(safy, 2019) rationale for choice of intervention: zirconomer improved, is a nano zirconia reinforced glass ionomer, which has improved the mechanical, esthetic and handling properties than its previous successor, zirconomer. zirconomer is commercialized as a white amalgam as it features mechanical properties similar to amalgam restorations. in this generation also, translucency is improved to be similar to the tooth structure.(shetty et al, 2017) as zirconomer improved is reinforced material, it is expected that has high wear resistance than the conventional glass ionomer restorations. (hesse et al., 2018)

Eligibility criteria:
inclusion criteria: * age group 18-55 * presence of occluding tooth. * good oral hygiene exclusion criteria: * poor periodontal status * adverse medical history. * potential behavioral problems
zanubrutinib in patients with waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma and follicular lymphoma

Conditions: Waldenström's Macroglobulinemia; Chronic Lymphocytic Leukemia; Marginal Zone Lymphoma; Follicular Lymphoma

Summary: the objective of this nis is to evaluate medical resource utilization, where data is rare in all cohorts, patient's qol and effectiveness of zanubrutinib treatment in adult patients with wm, cll, mzl and fl in a real-world setting.

ariadne will collect and analyze data of adult patients with wm, cll, mzl or fl in need of treatment. the study will explore the medical resource utilization during therapy with zanubrutinib (brukinsa®). further aims are to assess effectiveness, safety and tolerability of the treatment as well as treatment satisfaction and biomarkers. these data will be supplemented by the assessment of patient-reported outcomes (pros)/ health-related quality of life (qol). since treatment options for mw, cll, mzl or fl are limited and the most important factor is to keep or improve qol of the patients, there is an urge for real-world clinical data of patients treated with zanubrutinib, especially focusing on patients already treated upfront with a btk inhibitor, older patients and patients with comorbidities.

Eligibility criteria:
inclusion criteria: * waldenström's macroglobulinemia (all treatment lines) or * chronic lymphocytic leukemia (all treatment lines) or * marginal zone lymphoma (≥2 treatment line and at least one anti-cd20 antibody-based previous therapy) * follicular lymphoma (≥3 treatment line) * signed and dated informed consent form * treatment with zanubrutinib according to current smpc for wm, cll and mzl * treatment with zanubrutinib + obinutuzumab for fl according to current smpc * treatment decision before inclusion into this non-interventional study * age ≥18 years. exclusion criteria: * contraindications according to smpc for patients with wm, cll, mzl or fl * participation in an interventional clinical trial during zanubrutinib treatment.

Keywords: waldenström's macroglobulinemia zanubrutinib brukinsa chronic lymphocytic leukemia marginal zone lymphoma follicular lymphoma
respiratory care in intensive care unit for neuromuscular patients

Conditions: Respiratory Failure

Summary: retrospective multicentric observational study exploring the population of adult neuromuscular patients presenting a respiratory distress requiring their admission in an intensive care unit (icu) for ventilatory support. research of markers associated with long term mortality and ventilatory status.


Eligibility criteria:
inclusion criteria: * patient \> 18 years old * first stay in a icu ward * inclusion period : admission in icu between 01/01/2007 and 31/12/2015 * presenting an acute respiratory distress at admission or during icu stay * diagnosis of neuromuscular disease confirmed before hospital discharge exclusion criteria: * absence of respiratory failure during icu stay (icu stay for monitoring or for a specialized invasive procedure in the absence of respiratory failure, for example) * neuromuscular disease not proven or uncertain diagnosis * anterior admission in icu ward for vital organ failure

Keywords: neuromuscular diseases muscular dystrophy amyotrophic lateral sclerosis acute respiratory failure respiratory care mechanical ventilation weaning intensive care unit critical care survival
median nerve excursion during neurodynamic mobilization

Conditions: CTS

Summary: this study will compare changes in longitudinal median nerve excursion when neck flexion and ipsilateral rotation are added to the standard median neurodynamic test1 (mnt1) position in patients with carpal tunnel syndrome (cts) and normal controls.

median nerve excursion will be assessed by ultrasonography during three positions: standard mnt1, neck flexion with mnt1, and ipsilateral rotation combined with mnt1. both arms will be tested. arm will be held in abduction to 90° - 110° and external rotation to 90°, forearm supination, elbow extension and wrist and fingers extension using a custom made splint. the standard mnt1 includes neck contralateral side flexion. then, the researcher will move the neck passively into rotation and flexion. passive range limit will be determined prior to testing using a goniometer and passive end feel. movement order will be randomized using an excel random function. every position will be tested three times. a single researcher will do all movements passively. nerve excursion will be measured in real time by the same ultrasonographer who is blinded to patients grouping.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild to moderate cts. * must be able to tolerate the entire standard mnt1 position. exclusion criteria: * severe cts. * symptoms referred to the neck. * limited neck flexion, rotation, and side bending ranges (\>10%). * history of upper quadrant trauma, dysfunction or surgery. * history of peripheral neuropathy or cervical radiculopathy. * history of systemic disease associated with neuropathies such as diabetes mellitus, connective tissue diseases, thyroid disease, or obesity.

Keywords: median nerve, carpal tunnel syndrome neurodynamic mobilization
long term outcome in icu treated covid-19: return to work

Conditions: Covid19

Summary: return to work (not being on sick leave) within one year after intensive care unit (icu) admission with coronavirus disease 2019 (covid-19) will be assessed. risk and risk factors for not having returned to work will be compared to patients admitted to hospital and general population controls. the icu population comprises all swedish icu patients with covid-19 with at least one year of follow up. the hospital admitted cohort comprises four hospital admitted patients with covid-19 per icu patient, matched on age, legal gender and region. the general population controls are matched to the icu patients in a one to four fashion on age, legal gender and region. icu patients are identified in the swedish intensive care registry. the hospital admitted patients are identified in the national patient registry and the population controls are identified in the population registry. data on socioeconomics and income are provided by the statistics sweden. data on comorbidity, medications and death are provided from the national board of health and welfare. finally, data on sick leave are provided from the swedish social insurance agency.


Eligibility criteria:
inclusion criteria: admitted to a swedish icu and registered in the swedish intensive care registry with the icd 10 diagnosis u07.1 before 31 july 2020. icu group. or admitted to hospital but not icu with the icd-10 diagnosis u07.1 in the national patient registry before 31 july 2020. hospital group. or randomly selected from the general population (and not included in the icu or hospital admitted cohorts), matched on age, legal gender and region (four per icu patient). population control group exclusion criteria: death within one year of inclusion. (for analysis of the secondary outcome). missing a swedish personal identification number

Keywords: long term outcome return to work covid-19 risk factors critical care
swetick - a prospective multicenter study of tick-borne diseases in sweden

Conditions: Tick-Borne Diseases

Summary: the purpose of the swetick project is to increase the knowledge of the various clinical presentations of emerging tick-borne diseases (etbd), to assess their importance for human health, to develop and validate laboratory methods for diagnosis of etbd, and to develop recommendations for knowledge-driven management of patients with suspected etbd within the swedish healthcare system.


Eligibility criteria:
inclusion criteria in tbd and non-tbd groups: * clinical suspicion of tick-borne disease (physician's assessment based on medical history, symptoms, clinical findings and sometimes laboratory results) exclusion criteria: * incapacitated to understand the study information and make decisions (adults and adolescents \>15 years)
light treatment to improve symptom management of fibromyalgia syndrome

Conditions: Fibromyalgia; FMS

Summary: the purpose of this study is to determine the effect a morning light treatment has on improving physical function, pain intensity, and pain sensitivity in people with fibromyalgia syndrome (fms).


Eligibility criteria:
inclusion criteria: • meet criteria for fibromyalgia syndrome (fms) exclusion criteria: * significant chronic disease * severe hearing or memory problems * pending medical leave applications at workplace * current pregnancy, breastfeeding, or actively trying to get pregnant * night work or travel outside the eastern time zone within 1 month of the study * other research participation * frequent number of special events during study period (weddings, concerts, exams, etc).

Keywords: circadian timing pain light
evaluation of b+ surface on early loading

Conditions: Jaw, Edentulous, Partially

Summary: the trial is designed as a consecutive enrollment prospective one-center study. a minimum of 30 patients will be included in the study. at implant installation, the implant will be randomized to one of the groups (control: conventional loading, 8 weeks; test: early loading, 4 weeks). samples of peri-implant crevicular fluid (picf) and intrasulcular plaque will be collected at -14, 0 (baseline: prosthesis delivery), 7 days and 1, 3, 6, 12 months. prosthesis will be fabricated and delivered as usual, i.e., approximately two weeks after the impressions are taken.


Eligibility criteria:
inclusion criteria: * patient \>18 and ≤75 years old * one missing tooth in the premolar or molar area with both opposing and adjacent teeth (mesial and distal). exclusion criteria: * one-stage bone augmentation * heavy smokers (\>10 cigarettes/day) * uncontrolled type 1 or 2 diabetes (hga1c\>8) * known auto-immune or inflammatory disease * severe hematologic disorders, such as hemophilia or leukemia * local or systemic infection that may compromise normal healing (e.g., extensive periapical pathology) * liver or kidney dysfunction/failure * currently receiving cancer treatment or within 18 months from completion of radio- or chemotherapy * long-term history of oral bisphosphonates use (i.e., 10 years or more) * history of intravenous bisphosphonates * long-term (\>3 months) history of antibiotics or drugs known to alter the inflammation and/or immunological system * severe osseous diseases (e.g., paget disease of bone) * pregnant women or nursing mothers * not able or not willing to follow instructions related to the study procedures
dose finding and safety of oral lde225 in patients with advanced solid tumors

Conditions: Advanced Solid Tumor Cancers; Medulloblastoma; Basal Cell Carcinoma

Summary: this first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of lde225 given orally on a daily dosing schedule in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of advanced solid tumor (including •medulloblastoma and basal cell carcinoma) * blood work criteria exclusion criteria: * patients with history of brain tumor (except recurrent medulloblastoma) or brain metastases * positive hiv, hepatitis b or c * impaired intestinal function * impaired heart function * pregnant or breast-feeding women other protocol-defined inclusion/exclusion criteria may apply

Keywords: advanced tumors hedgehog smoothened inhibitor
efficacy and safety of tac and exemestane as neoadjuvant chemotherapy in the postmenopausal women with breast cancer

Conditions: Breast Cancer

Summary: select the postmenopausal patients with breast cancer who is confirmed by core needle biopsy and at the clinical stage t2-4n0-2m0.treat them with 4 cycles of tac as neoadjuvant chemotherapy (docetaxel was 75mg/m2, the epi 60mg/m2 and the ctx 600mg/m2,21day/cycle).at the same time give daily oral exemestane 25mg for 12 weeks.then assess the efficacy and safety of tac and exemestane.

the investigators select the postmenopausal patients with breast cancer who is confirmed by core needle biopsy and at the clinical stage t2-4n0-2m0.treat them with 4 cycles of tac as neoadjuvant chemotherapy (docetaxel was 75mg/m2, the epi 60mg/m2 and the ctx 600mg/m2,21day/cycle).at the same time give daily oral exemestane 25mg for 12 weeks.then assess the efficacy and safety of tac and exemestane.

Eligibility criteria:
inclusion criteria: 1. karnofsky ≥ 70 2. provision of informed consent 3. pathological confirmation of invasive ductal carcinoma and estrogen receptor is positive 4. tumor stage(tnm):t2-4bn0-3m0 5. premenopausal woman 6. not previously received treatment with bisphosphonate 7. laboratory criteria: * plt ≥ 100\*109/l * wbc ≥ 4000/mm3 * hgb ≥ 10g/dl * got,gpt,alp ≤ 2\*uln * tbil,dbil,ccr ≤ 1.5\*uln exclusion criteria: 1. pregnant or lactation woman 2. history of organ transplantation 3. with mental disease 4. with severe infection or active gastrointestinal ulcers 5. with severe liver disease (such as cirrhosis), kidney disease, respiratory disease or diabetes 6. disease-free period of other malignant tumor is less than 5 years(except cured basal cell skin cancer and cervical carcinoma in situ) 7. with heart disease 8. experimental drug allergy
the effects of pfmt and mpe in elderly women with sui.

Conditions: Stress Urinary Incontinence; Pelvic Floor Disorders; Aging

Summary: the aim of the study was to compare the effects of pfmt and mpe on sui frequency and explosure from symptoms, pfm activation response and strength of lumbar stabilizing muscle in elderly women with sui.

stress urinary incontinence (sui) is associated with situations which bladder pressure exceeds the pressure at which the urethra has the capacity to remain closed, such as physical exertion, coughing, and sneezing. sui is more predominant in women worldwide, with a prevalence ranging from 10% in young women to 45% in the elderly. physiotherapy interventions in sui include patient education including recommendations for bladder and/or bowel training, fluid management, and diet modification; modalities for decrease pain; pelvic floor muscle training (pfmt) with or without biofeedback and/or electrical stimulation to improve strength and coordination of the pelvic floor muscle (pfm) and stabilization exercises to improve strength of abdominal and/or lumbar stabilizer muscles. pfmt includes repetitive contraction of the pfm, which increases perineal support and improves the muscle tone of the pfm. modified pilates exercises (mpe) is a mind-body approach that includes slow, controlled movements that focus on posture and breathing. the aim of the study was to compare the effects of pfmt and mpe on sui frequency and explosure from symptoms, pfm activation response and strength of lumbar stabilizing muscle in elderly women with sui. in this study, thirty-four elderly women who were diagnosed with sui were randomized into group 1: pfmt (n=17) or group 2: mpe (n=17). both groups performed their exercises twice a week for 12 weeks and accompanied by a physiotherapist. incontinence severity index (isi), urogenital distress inventory-short form (udi-6) and incontinence impact questionnaire-short form (iiq-7) were used to assess sui frequency and explosure from symptoms, electromyography (emg) device was used to assess pfm activation response and a stabilizer was used to assess strength of lumbar stabilizing muscle. the assessments were performed at baseline and after 12 week treatment. the effect size was calculated for the assessments used in the study.

Eligibility criteria:
inclusion criteria: 1. being volunteer to participate in a study; 2. being a woman over the age of 65; 3. having the diagnosis of sui; 4. participants who scored at least 24 on the mini mental state exam (mmse). exclusion criteria: 1. having a neurological disease; 2. having pfm which cannot contract; 3. having a urinary tract infection; 4. having the stage two or higher pelvic organ prolapse; and 5. participants who received a sui treatment in the recent year.

Keywords: aging exercise pelvic floor urinary incontinence women
effect of casodex on tumour hypoxia - prostate cancer

Conditions: Prostatic Neoplasms

Summary: prostate cancers, in common with many other tumours, are often hypoxic; that is, they have low levels of oxygen. it is thought that tumour hypoxia may hasten the progression of cancers and make them more resistant to treatment. one previous study has suggested that hormone therapy, such as casodex, may improve the prostate oxygen level. this study is designed to test that finding.


Eligibility criteria:
inclusion criteria: * men with histologically proven prostatic carcinoma, stage ct2, n0, m0, receiving neoadjuvant bicalutamide plus conformal radiotherapy in study 9907, who have previously participated in the prostate cancer hypoxia project * informed consent exclusion criteria: * coagulopathy
effect of dialysis on the pharmacokinetics of telavancin in patients with chronic kidney disease stage 5

Conditions: End-Stage Renal Disease; Stage 5 Chronic Kidney Disease

Summary: chronic kidney disease stage 5 (ckd5) patients receiving maintenance hemodialysis are at an increased risk for developing bloodstream infections. vancomycin is traditionally used as first-line therapy for treating these infections, but the emergence of less-susceptible bacterial strains necessitates the consideration of alternative antibiotic therapy. telavancin is a new antibiotic that has broad-spectrum antimicrobial activity against gram-positive bacteria, including vancomycin-intermediate staphylococcus aureus. while dosing recommendations for telavancin are available for patients with normal kidney function, there are no published recommendations for ckd5 patients receiving hemodialysis. a pharmacokinetic study is needed to characterize the pharmacokinetic parameters of telavancin in these patients to determine the extent of drug removal by hemodialysis and to establish dosing recommendations for ckd5 patients on maintenance hemodialysis.


Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * within 50 - 150 % of ideal body weight and greater than 40 kg * ckd5 receiving maintenance hemodialysis for ≥ 3 months * creatinine clearance estimate \< 10 ml/min * not received telavancin within the past month * no concurrent illness or evidence of infection * able to give informed consent exclusion criteria: * pre-study hemoglobin \< 9.0 g/dl * plasma albumin \< 2.5 g/dl * pregnancy * breastfeeding * qtc interval \> 470 msec on ekg obtained within the last 6 months * receiving concomitant qt prolonging agents * receiving warfarin or low molecular weight heparin products * known allergy to telavancin or vancomycin * unstable blood pressure control * need for routine large fluid removal during dialysis (\> 4 liters) * diagnosis of liver disease with a child pugh score of c or higher * dialysis isolation requirements due to hepatitis b * participating concurrently in another investigational drug study

Keywords: telavancin end-stage renal disease esrd pharmacokinetics hemodialysis chronic kidney disease ckd dialysis vibativ
inhaled extra-fine hydrofluoalkane-beclomethasone (qvar) in premature infants with bronchopulmonary dysplasia (bpd)

Conditions: Bronchopulmonary Dysplasia

Summary: premature infants with chronic lung disease (bronchopulmonary dysplasia \[bpd\]) are commonly treated with inhaled steroids, an optional treatment according to textbooks and guidelines . however, the evidence supporting this treatment in spontaneously breathing infants is limited, and based on only two randomized, placebo-controlled trials (rct) with relative small number of infants . the cochrane review concluded that these studies do not allow firm conclusions with regard to the efficacy of inhaled steroids in non-ventilated infants . thus, there is no doubt that there is a need for more rct in order to ascertain the role of inhaled steroids in infants with bpd. because of its physical properties that theoretically make qvar an attractive therapy in infants and studies showing it to be as effective as and with similar safety profile as other inhaled steroids in children, the investigators hypothesized that inhaled qvar will be an effective therapy in infants with bpd.


Eligibility criteria:
inclusion criteria: 1. preterm infants with moderate to severe bpd, defined as oxygen \ 30% or with positive pressure support at 36 weeks corrected gestational age, respectively 2. parents signed an informed consent 3. the parents will comply with the 3 months study follow-up requirements, as judged by the site principal investigator. exclusion criteria: 1. congenital malformation 2. cardiac disease (including active pda) 3. intraventricular hemorrhage grade iii-iv 4. unstable conditions such as sepsis, apneas, ets. at time of enrollment.

Keywords: inhaled steroids bronchopulmonary dysplasia infants with moderate to severe bpd